智通财经APP获悉,强生(JNJ.US)日前宣布,美国FDA已授予其靶向新生儿Fc受体(FcRn)的在研抗体疗法nipocalimab突破性疗法认定(BTD),用于治疗中度至重度干燥综合征(Sjögren’s disease,SjD)成人患者。根据新闻稿,nipocalimab是在SjD领域获得BTD的首个疗法。值得一提的是,这款疗法今年年初被行业媒体Evaluate列为10大潜在重磅在研疗法之一。
Nipocalimab是一款潜在“best-in-class”,靶向FcRn的抗体疗法。它通过与FcRn结合,让被单核细胞和内皮细胞摄入的自身抗体不会重新释放到血液中,而是在细胞内被降解。已有研究显示,它可以将血液循环中包括致病自身抗体在内的IgG水平降低超过75%。这款抗体疗法有望治疗多种自身抗体介导的免疫疾病。
此前,它已经获得FDA授予的突破性疗法认定,用于治疗有高风险出现严重新生儿溶血病(HDFN)的孕妇。Nipocalimab在治疗成人全身性重症肌无力(gMG)成人患者的关键性3期临床试验VIVACITY中也已获得积极顶线结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.